Cite Filings / CTNM / 0001193125-26-052863
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13G

Statement of Beneficial Ownership

Contineum Therapeutics, Inc. · Filed 2026-02-17 · Acc 0001193125-26-052863

Documents 1

  • SCHEDULE 13G Statement of Beneficial Ownership , xslSCHEDULE_13G_X01/primary_doc.xml

Around this filing

  • 2026-02-20 4 Chief Scientific Officer sold 100 shares at $16.00 ($1,600)
  • 2026-02-17 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2026-02-17 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-02-17 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-02-13 4 CEO and President sold 400 shares at $16.00 ($6,400)
  • 2026-02-13 4 Chief Scientific Officer sold 400 shares at $16.00 ($6,400)
  • 2025-07-25 SCHEDULE 13G Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · JANUS HENDERSON GROUP Ltd. 4.6%
  2. 2026-11-16 SCHEDULE 13G/A · BALYASNY ASSET MANAGEMENT L.P. 7.35%
  3. 2026-10-28 SCHEDULE 13G/A · Franklin Templeton, Inc. 5.2%
Loading xslSCHEDULE_13G_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…